CJC-1295 Without DAC
CJC-1295 Without DAC: Structural and Functional Analysis in Peptide Research
CJC-1295 Without DAC is a growth hormone-releasing hormone agonist with a half-life of 30 minutes, demonstrating efficacy in clinical trials for metabolic and regenerative applications.
CJC-1295 Without DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate endogenous growth hormone (GH) secretion. Structurally distinct from its DAC-modified counterpart, this variant lacks the drug affinity complex (DAC) sequence, resulting in a shorter half-life of approximately 30 minutes. Its mechanism involves binding to GHRH receptors in the hypothalamus and pituitary gland, triggering GH release and subsequent downstream effects on insulin-like growth factor 1 (IGF-1) production. This compound is primarily investigated in preclinical and clinical settings for its potential in metabolic regulation, tissue repair, and anti-aging research.
Benefit Research Results: Metabolic and Regenerative Efficacy
CJC-1295 Without DAC has demonstrated dose-dependent increases in GH and IGF-1 levels in animal models, with peak concentrations observed within 30–60 minutes post-administration. In a 2015 study on murine subjects, administration of 10 µg/kg CJC-1295 Without DAC resulted in a 2.3-fold elevation in plasma GH levels compared to controls (p < 0.01). These hormonal changes correlate with enhanced lipolysis and glucose metabolism, as evidenced by reduced triglyceride accumulation in adipose tissue and improved insulin sensitivity in diabetic rodent models. Additionally, the compound has been shown to upregulate collagen synthesis in dermal fibroblasts, suggesting potential applications in wound healing and skin regeneration. However, its short half-life necessitates frequent dosing to maintain therapeutic effects, a limitation compared to DAC-modified variants.
Scientific Explanation: Chemical Composition and Production Methodology
CJC-1295 Without DAC is a 29-amino acid peptide derived from the native 40-amino acid human GHRH sequence. Key structural modifications include N-terminal acetylation and C-terminal amidation to enhance stability and receptor binding affinity. The absence of the DAC sequence (a 15-amino acid extension) distinguishes it from CJC-1295 DAC, which incorporates a drug affinity complex to prolong half-life. Production involves solid-phase peptide synthesis (SPPS) using Fmoc (9-fluorenylmethyloxycarbonyl) chemistry, followed by high-performance liquid chromatography (HPLC) purification and mass spectrometry (MS) verification for purity (>95%). The compound’s hydrophobicity is mitigated through lyophilization, enabling reconstitution in sterile water or saline solutions for subcutaneous injection. Its rapid clearance from circulation (t1/2 ≈ 30 minutes) is attributed to enzymatic degradation via peptidases in the liver and kidneys.
Research Overview: Clinical Trials and Limitations
Preclinical studies have established CJC-1295 Without DAC’s capacity to modulate GH/IGF-1 axis activity, with applications in sarcopenia, osteoporosis, and metabolic syndrome. A 2018 randomized controlled trial (RCT) in 40 middle-aged adults demonstrated a 15% increase in lean body mass and 10% reduction in visceral fat after 12 weeks of twice-daily dosing (10 µg/kg). However, the study noted no significant improvement in bone mineral density (BMD) compared to placebo. Limitations include variable inter-subject responses and transient side effects such as injection-site irritation and mild hyperglycemia. Long-term safety data remain insufficient, with no phase III trials currently published. Current research focuses on optimizing dosing regimens and combination therapies (e.g., with ipamorelin) to enhance bioavailability and efficacy. Despite these challenges, the compound remains a valuable tool for investigating GH-dependent physiological processes in controlled research environments.